John Temperato

John Temperato

Sales & Marketing chez SALIX PHARMACEUTICALS, LTD.

Fortune : - $ au 31/03/2024

59 ans
Health Technology
Consumer Services
Commercial Services

Profil

John Temperato is currently the Director at Naia Rare Diseases LLC and holds a position as a Member at the Academy of Managed Care Pharmacy.
He is also a Senior Vice President-Sales & Managed Markets at Salix Pharmaceuticals Ltd.
In the past, he served as the Chief Executive Officer at RDD Pharma Ltd.
and held the position of President & Chief Operating Officer at Atlantic Healthcare Plc, Melinta Subsidiary Corp., and Melinta Therapeutics, Inc. He was also the President, Chief Executive Officer & Director at 9 Meters Biopharma, Inc. Mr. Temperato completed his undergraduate degree at the University of Bridgeport.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
24/04/2023 105 785 ( 0,73% ) - $ 31/03/2024

Postes actifs de John Temperato

SociétésPosteDébut
SALIX PHARMACEUTICALS, LTD. Sales & Marketing -
Corporate Officer/Principal -
Director/Board Member 01/01/2020
Tous les postes actifs de John Temperato

Anciens postes connus de John Temperato

SociétésPosteFin
9 METERS BIOPHARMA, INC. Chief Executive Officer 26/05/2023
Chief Executive Officer 01/01/2020
President -
MELINTA THERAPEUTICS, INC. President -
President -
Voir l'expérience en détail de John Temperato

Formation de John Temperato

University of Bridgeport Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de John Temperato

Relations

45

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées1
9 METERS BIOPHARMA, INC.

Health Technology

Entreprise privées7

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. John Temperato